http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. The FDA has approved a thyroid cancer drug successfully tested at Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute (TGen). http://medicalxpress.com/news/2013-03-cancer-drug-clinical-trial-fda.html Cancer Wed, 27 Mar 2013 09:56:56 EST news283597005 A new vaccine that has raised hopes of becoming a potent new tool in the battle against malaria seems to stop working in children after four years, according to research published Wednesday. http://medicalxpress.com/news/2013-03-malaria-vaccine-years.html Medications Wed, 20 Mar 2013 17:14:46 EST news283018479 The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented today at the American College of Cardiology's 62nd Annual Scientific Session. http://medicalxpress.com/news/2013-03-cangrelor-superior-clopidogrel-champion-phoenix.html Cardiology Mon, 11 Mar 2013 10:50:01 EST news282215735 The median age of patients diagnosed with advanced non–small-cell lung cancer (NSCLC) has steadily increased over the recent years and is presently 70 years. Despite this, the elderly are significantly underrepresented in clinical trials. A recent study published in the March 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, investigated the degree to which exclusion or underrepresentation of elderly occurs in practice-changing clinical trials in advanced NSCLC. Researchers conclude that greater representation of elderly patients in phase III trials is required to better define evidence-based paradigms in the increasingly elderly NSCLC population. http://medicalxpress.com/news/2013-02-greater-representation-elderly-patients-phase.html Cancer Fri, 22 Feb 2013 09:33:41 EST news280748016 Spin and bias exist in a high proportion of published studies of the outcomes and adverse side-effects of phase III clinical trials of breast cancer treatments, according to new research published in the cancer journal Annals of Oncology today. http://medicalxpress.com/news/2013-01-bias-published-breast-cancer-trials.html Cancer Wed, 09 Jan 2013 19:30:01 EST news276960715 German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations. http://medicalxpress.com/news/2012-12-germany-merck-setback-cancer-drug.html Medications Wed, 19 Dec 2012 11:32:50 EST news275139163 (Medical Xpress)—Results of a University of Arizona Cancer Center's scientist-led clinical trial show that a drug already approved for breast and lung cancer improved progression-free survival in patients with metastatic melanoma. http://medicalxpress.com/news/2012-11-cancer-drug-survival-patients-metastatic.html Cancer Wed, 14 Nov 2012 08:20:40 EST news272103570 A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce a particular kind of brain tumor in patients with tuberous sclerosis complex (TSC)—a genetic disease that causes tumors to grow on vital organs. http://medicalxpress.com/news/2012-11-drug-brain-tumors-children-tuberous.html Cancer Tue, 13 Nov 2012 18:30:04 EST news272046793 (Medical Xpress)—Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their disease, results from a major phase III Cancer Research UK-funded trial led by Cardiff University show today. http://medicalxpress.com/news/2012-11-antibody-conjugate-drug-survival-older.html Cancer Mon, 12 Nov 2012 09:40:01 EST news271934631 A drug which 'reboots' a person's immune system has been shown to be an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they were treated (a 'first-line' therapy), as well as affected individuals who were previously untreated. The results of these two phase III clinical trials were published today in the journal The Lancet. http://medicalxpress.com/news/2012-10-ms-drug-effective.html Neuroscience Wed, 31 Oct 2012 20:18:12 EST news270933478 Cannabis seems to ease the painful muscle stiffness typical of multiple sclerosis, indicate phase III trial results, published in the Journal of Neurology Neurosurgery and Psychiatry. http://medicalxpress.com/news/2012-10-cannabis-eases-sclerosis-stiffness.html Neuroscience Tue, 09 Oct 2012 04:33:59 EST news268976030 New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. http://medicalxpress.com/news/2012-10-phase-iii-treatment-renal-cell.html Cancer Mon, 01 Oct 2012 03:32:58 EST news268281169 The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. http://medicalxpress.com/news/2012-09-phase-iii-trial-crizotinib-superior.html Cancer Sun, 30 Sep 2012 06:11:59 EST news268204105 New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. http://medicalxpress.com/news/2012-09-advances-gastrointestinal-cancer-treatments.html Cancer Sat, 29 Sep 2012 05:16:08 EST news268114542 Chronic, debilitating pain and potential organ failure are what approximately 100,000 sickle cell patients in the United States live with each day. Yutaka Niihara, M.D., M.P.H. - lead investigator at The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and co-founder of Emmaus Medical, Inc., an LA BioMed spin-off company - is developing a low-cost, noninvasive treatment that helps provide relief for patients suffering from the debilitating effects of sickle cell disease. http://medicalxpress.com/news/2012-09-therapy-ease-pain-sickle-cell.html Diseases, Conditions, Syndromes Tue, 25 Sep 2012 11:08:06 EST news267790071 (HealthDay)—Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-09-l-carnitine-cancer-related-fatigue.html Cancer Tue, 18 Sep 2012 13:07:42 EST news267192445 German pharmaceuticals maker Merck KGaA said Tuesday it is withdrawing its application for its drug Erbitux to be used to treat patients with lung cancer. http://medicalxpress.com/news/2012-09-merck-kgaa-setback-cancer-drug.html Cancer Tue, 18 Sep 2012 04:04:10 EST news267159836 The first trial to study the effect of platelet inhibition in patients with acute coronary syndromes managed medically without revascularisation has found no significant difference between prasugrel and clopidogrel in the prevention of death, myocardial infarction or stroke. http://medicalxpress.com/news/2012-08-prasugrel-clopidogrel-acs-patients-revascularisation.html Cardiology Mon, 27 Aug 2012 10:44:03 EST news265283032 Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer. http://medicalxpress.com/news/2012-08-enzalutamide-months-survival-late-stage-prostate.html Cancer Thu, 16 Aug 2012 10:33:22 EST news264331988 The head of one of the UK's leading cancer research organisations has hailed a golden age in prostate cancer drug discovery as for the fourth time in two years results are published finding a new drug can significantly extend life. http://medicalxpress.com/news/2012-08-golden-age-prostate-cancer-treatment.html Cancer Wed, 15 Aug 2012 17:00:02 EST news264261259 Treatment with denosumab resulted in a greater reduction in skeletal-related events in patients with breast cancer that spread to the bones compared with zoledronic acid, while also maintaining health-related quality of life, according to the results of a phase III study published in Clinical Cancer Research. http://medicalxpress.com/news/2012-08-denosumab-superior-zoledronic-acid-breast.html Cancer Tue, 14 Aug 2012 13:00:01 EST news264160012 The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. An international team led by Mount Sinai School of Medicine scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice. http://medicalxpress.com/news/2012-08-drug-toxic-substance-common-alzheimer.html Neuroscience Mon, 13 Aug 2012 11:31:28 EST news264076253 (Medical Xpress) -- A new study involving researchers from Karolinska Institutet demonstrates the efficacy of Tofacitinib, a new drug for rheumatoid arthritis. According to the study, which is published in The New England Journal of Medicine, the drug is just as effective as biological medicines, but unlike them can be taken in tablet form. http://medicalxpress.com/news/2012-08-efficacy-rheumatoid-arthritis-drug.html Arthritis & Rheumatism Thu, 09 Aug 2012 04:13:33 EST news263704405 An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease. The findings, published July 31, 2012 in Molecular Psychiatry, demonstrate renewed potential for this compound and could lead to clinical trials in patients with early stages of the disease. http://medicalxpress.com/news/2012-07-alzheimer-drug-potential.html Psychology & Psychiatry Tue, 31 Jul 2012 04:00:01 EST news262888215 A drug designed to shield the heart from injury during bypass surgery failed to reduce deaths, strokes and other serious events among patients at high risk of complications, according to a large, prospective study lead by researchers at Duke University Medical Center. http://medicalxpress.com/news/2012-07-drug-curb-heart-bypass-complications.html Cardiology Tue, 10 Jul 2012 16:00:01 EST news261152602 German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients. http://medicalxpress.com/news/2012-07-merck-kgaa-setback-cancer-drug.html Cancer Thu, 05 Jul 2012 08:00:31 EST news260694026 (HealthDay) -- A large proportion of patients with moderate-to-severe plaque psoriasis are underdiagnosed and undertreated for cardiovascular (CV) risk factors, according to a study published in the July issue of the Journal of the American Academy of Dermatology. http://medicalxpress.com/news/2012-06-psoriasis-patients-undertreated-cv-factors.html Diseases, Conditions, Syndromes Fri, 22 Jun 2012 10:40:01 EST news259577534 Prostate cancer patients with advanced tumors that have spread to bone have a poor chance of surviving. Patients with the disease may now live longer with a new line of radioisotope therapy, say researchers at the Society of Nuclear Medicine's 2012 Annual Meeting. http://medicalxpress.com/news/2012-06-therapy-life-prostate-cancer-patients.html Cancer Mon, 11 Jun 2012 13:14:00 EST news258639217 A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients with active psoriatic arthritis (PsA) treated with Ustekinumab (UST) 90mg were more than twice as likely to achieve the study's primary endpoint, ACR20* at 24 weeks, than those treated with placebo (49.5% vs 22.8%). 42.4% of patients treated with UST 45mg were also more likely to achieve ACR20 at 24 weeks compared to placebo. http://medicalxpress.com/news/2012-06-patients-psa-ustekinumab-acr20-placebo.html Arthritis & Rheumatism Fri, 08 Jun 2012 04:16:02 EST news258347752 A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint of ACR20* response at week 12 than those on placebo: 58% on CZP200mg Q2W; and 51.9% on CZP 400 mg Q4W compared to 24.3% on placebo. http://medicalxpress.com/news/2012-06-patients-certolizumab-pegol-acr20-placebo.html Arthritis & Rheumatism Thu, 07 Jun 2012 08:20:01 EST news258273799